Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 37,916,180 | 41,475,020 | 41,895,770 | 43,939,700 | 43,902,540 |
| Cost of Goods | 12,069,030 | 13,433,800 | 12,512,770 | 11,763,460 | 11,739,500 |
| Gross Profit | 25,847,150 | 28,041,210 | 29,382,990 | 32,176,240 | 32,163,040 |
| Operating Expenses | 20,429,870 | 17,650,170 | 17,666,700 | 19,651,140 | 26,313,870 |
| Operating Income | 5,417,309 | 10,391,850 | 11,717,070 | 12,525,560 | 5,849,672 |
| Interest Expense | 1,198,160 | 1,200,200 | 1,280,760 | 0 | 0 |
| Other Income | 672,411 | 1,209,570 | 171,170 | -174,890 | -968,012 |
| Pre-tax Income | 4,891,560 | 10,401,220 | 10,607,480 | 12,350,670 | 4,881,660 |
| Income Tax | 225,780 | 1,594,530 | 3,087,770 | 3,593,850 | 2,016,370 |
| Net Income Continuous | 6,905,888 | 8,510,936 | 8,775,114 | 9,038,523 | 9,926,282 |
| Net Income | $4,665,770 | $8,806,690 | $7,519,710 | $8,756,810 | $2,865,290 |
| EPS Basic Total Ops | 2.16 | 4.41 | 3.69 | 4.11 | 1.30 |
| EPS Basic Continuous Ops | 3.59 | 4.40 | 4.47 | 4.49 | 4.88 |
| EPS Diluted Total Ops | 2.14 | 4.34 | 3.69 | 4.06 | 1.29 |
| EPS Diluted Continuous Ops | 3.55 | 4.33 | 4.47 | 4.43 | 4.84 |
| EBITDA(a) | $8,756,358 | $12,606,040 | $13,436,900 | $15,216,130 | $9,052,052 |